IN2015DN02573A - - Google Patents

Download PDF

Info

Publication number
IN2015DN02573A
IN2015DN02573A IN2573DEN2015A IN2015DN02573A IN 2015DN02573 A IN2015DN02573 A IN 2015DN02573A IN 2573DEN2015 A IN2573DEN2015 A IN 2573DEN2015A IN 2015DN02573 A IN2015DN02573 A IN 2015DN02573A
Authority
IN
India
Prior art keywords
pulmonary fibrosis
compound
present
formula
idiopathic
Prior art date
Application number
Inventor
Ulf; Nilsson
Hakon; Leffler
Neil; Henderson
Tariq; Sethi
Alison; Mackinnon
Original Assignee
Galecto Biotech Ab
Univ Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2794066A external-priority patent/CA2794066C/en
Priority claimed from US13/832,672 external-priority patent/US9243021B2/en
Application filed by Galecto Biotech Ab, Univ Edinburgh filed Critical Galecto Biotech Ab
Publication of IN2015DN02573A publication Critical patent/IN2015DN02573A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/001—Details of inhalators; Constructional features thereof with means for agitating the medicament using ultrasonic means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0085—Inhalators using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Abstract

The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis , such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis , such as Idiopathic pulmonary fibrosis in a human subject.
IN2573DEN2015 2012-10-31 2013-10-30 IN2015DN02573A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261720641P 2012-10-31 2012-10-31
CA2794066A CA2794066C (en) 2012-10-31 2012-10-31 Galactoside inhibitor of galectins
CA2795753A CA2795753A1 (en) 2012-10-31 2012-11-15 Novel galactoside inhibitor of galectins
US13/832,672 US9243021B2 (en) 2012-10-31 2013-03-15 Galactoside inhibitor of galectins
PCT/EP2013/072691 WO2014067986A1 (en) 2012-10-31 2013-10-30 Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Publications (1)

Publication Number Publication Date
IN2015DN02573A true IN2015DN02573A (en) 2015-09-11

Family

ID=52686686

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2573DEN2015 IN2015DN02573A (en) 2012-10-31 2013-10-30

Country Status (7)

Country Link
EP (2) EP3278805A1 (en)
JP (1) JP2015535233A (en)
CN (1) CN104755088A (en)
CA (1) CA2884802A1 (en)
ES (1) ES2817888T3 (en)
IN (1) IN2015DN02573A (en)
WO (1) WO2014067986A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9243021B2 (en) 2012-10-31 2016-01-26 Galecto Biotech Ab Galactoside inhibitor of galectins
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins
ES2784873T3 (en) * 2014-07-09 2020-10-01 Galecto Biotech Ab Novel hybrid galactoside inhibitor of galectins
ES2776255T3 (en) 2015-01-16 2020-07-29 Galecto Biotech Ab Novel galectin galactoside inhibitor
EP3828191A3 (en) * 2015-01-30 2021-08-18 Galecto Biotech AB Novel galactoside inhibitor of galectins
EP3294293B1 (en) 2015-05-12 2020-11-18 Galecto Biotech AB Once-daily treatment of pulmonary fibrosis
JP6915956B2 (en) * 2015-05-15 2021-08-11 ガレクト・バイオテック・エイビイ Treatment of pulmonary fibrosis once daily
US10799522B2 (en) * 2015-07-27 2020-10-13 Wayne State University Compositions and methods relating to galectin detection
ES2921500T3 (en) 2015-11-09 2022-08-26 Galecto Biotech Ab 1,1'-sulfanediyl-di-beta-d-galactopyranosides as inhibitors of galectins
EP3390423B1 (en) 2015-12-18 2022-08-03 Galecto Biotech AB Polymorphic forms and process
JP7086008B2 (en) * 2016-03-04 2022-06-17 ガレクティン・サイエンシーズ・リミテッド・ライアビリティ・カンパニー Serenogalactoside compounds and their use for the prevention and treatment of galactin-related diseases
EP3484904A1 (en) * 2016-07-12 2019-05-22 Galecto Biotech AB Alpha-d-galactoside inhibitors of galectins
WO2018011093A1 (en) 2016-07-12 2018-01-18 Galecto Biotech Ab Alpha-d-galactoside inhibitors of galectins
US11576924B2 (en) * 2017-05-12 2023-02-14 Galectin Sciences, Llc Compounds for the prevention and treatment of diseases and the use thereof
WO2019067702A1 (en) 2017-09-27 2019-04-04 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2019075045A1 (en) 2017-10-11 2019-04-18 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
EP3732186A1 (en) 2017-12-29 2020-11-04 GlycoMimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
EA202091684A1 (en) 2018-01-10 2020-12-04 Галекто Биотек Аб NEW GALACTOSIDE GALECTIN INHIBITOR
CN112292386A (en) * 2018-06-15 2021-01-29 百时美施贵宝公司 Tetrahydropyran-based thiodisaccharide mimetics as galectin-3 inhibitors
US20210138080A1 (en) * 2018-06-29 2021-05-13 Glykos Biomedical Oy Conjugates
US20210380624A1 (en) 2018-10-15 2021-12-09 Galecto Biotech Ab Galactoside inhibitor of galectins
WO2020078807A1 (en) 2018-10-15 2020-04-23 Galecto Biotech Ab Prodrug of galactoside inhibitors of galectins
US11447517B2 (en) 2018-11-21 2022-09-20 Galecto Biotech Ab Galactoside inhibitor of galectins
EP3891144A1 (en) 2018-12-06 2021-10-13 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
CA3122321A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
WO2020139962A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
WO2020198266A1 (en) 2019-03-26 2020-10-01 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US20220144818A1 (en) 2019-04-10 2022-05-12 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
WO2020248068A1 (en) * 2019-06-14 2020-12-17 UNIVERSITé LAVAL Synthesis of 3-azido-3-deoxy-d-galactopyranose
CN114222749A (en) * 2019-06-24 2022-03-22 格莱克特生物技术公司 Large scale process for 3,3' -dideoxy-3, 3' -bis- [4- (3-fluorophenyl) -1H-1,2,3-triazol-1-yl ] -1,1' -sulfonamido-di-beta-D-galactopyranoside
CA3143079A1 (en) 2019-07-03 2021-01-07 Galecto Biotech Ab Novel galactoside inhibitor of galectins
JP2022538635A (en) 2019-07-03 2022-09-05 ガレクト バイオテック エービー Novel galactoside inhibitors of galectins
CA3143078A1 (en) 2019-07-05 2021-01-14 Galecto Biotech Ab Novel galactoside inhibitor of galectins
EP4010076B1 (en) 2019-08-09 2024-01-17 Idorsia Pharmaceuticals Ltd (hetero)aryl-methyl-thio-beta-d-galactopyranoside derivatives
CN114269737A (en) 2019-08-15 2022-04-01 爱杜西亚药品有限公司 2-hydroxycycloalkane-1-carbamoyl derivatives
WO2021038068A1 (en) 2019-08-29 2021-03-04 Idorsia Pharmaceuticals Ltd Alpha-d-galactopyranoside derivatives
US20230038373A1 (en) 2019-12-18 2023-02-09 Glykos Biomedical Oy Stabile conjugate
US20230107479A1 (en) * 2020-03-23 2023-04-06 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
US20230137160A1 (en) * 2020-03-31 2023-05-04 Galecto Biotech Ab Large scale process for preparing 1,2,4, 6-tetra-o-acetyl-3-azido-3-deoxy-d-galactopyranoside
WO2021226002A1 (en) 2020-05-05 2021-11-11 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US20230212158A1 (en) 2020-05-11 2023-07-06 Bristol-Myers Squibb Company Small molecule inhibitors of galectin-3
US20230303538A1 (en) 2020-05-28 2023-09-28 Bristol-Myers Squibb Company Galectin-3 inhibitors
EP4225752A1 (en) 2020-10-06 2023-08-16 Idorsia Pharmaceuticals Ltd Spiro derivatives of alpha-d-galactopyranosides
MX2023005039A (en) 2020-11-02 2023-05-16 Idorsia Pharmaceuticals Ltd Galectin-3 inhibiting 2-hydroxycycloalkane-1 -carbamoyl derivatives.
CN116806219A (en) 2021-02-09 2023-09-26 爱杜西亚药品有限公司 Hydroxy-heterocylic-carbamoyl derivatives
TW202300146A (en) 2021-03-03 2023-01-01 瑞士商愛杜西亞製藥有限公司 Triazolyl-methyl substituted alpha-d-galactopyranoside derivatives

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3470380D1 (en) 1984-08-09 1988-05-19 Inge Brugger Nebulizer
US5152456A (en) 1989-12-12 1992-10-06 Bespak, Plc Dispensing apparatus having a perforate outlet member and a vibrating device
GB9027234D0 (en) 1990-12-15 1991-02-06 Harris Pharma Ltd An inhalation device
DE69230613T2 (en) 1991-07-02 2000-12-28 Inhale Inc METHOD AND DEVICE FOR DISPENSING MEDICINES IN AEROSOL FORM
AU725348B2 (en) 1996-01-03 2000-10-12 Glaxo Group Limited Inhalation device
DE19726110C2 (en) 1997-06-20 1999-07-22 Draegerwerk Ag Aerosol generator for ventilation systems
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE10102846B4 (en) 2001-01-23 2012-04-12 Pari Pharma Gmbh aerosol generator
ATE269735T1 (en) 2001-10-18 2004-07-15 Pari Gmbh INHALATION THERAPY DEVICE
WO2003045383A1 (en) * 2001-11-26 2003-06-05 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
DE60235883D1 (en) 2002-08-02 2010-05-20 Pari Pharma Gmbh Device for generating liquid droplets
DE10250625A1 (en) 2002-10-30 2004-05-19 Pari GmbH Spezialisten für effektive Inhalation Inhalation therapy device
DE10257381B4 (en) 2002-12-09 2006-09-14 Pari GmbH Spezialisten für effektive Inhalation Inhalation therapy device
SE0401300D0 (en) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel Galactoside Inhibitors of Galectins
SE0401301D0 (en) 2004-05-21 2004-05-21 Forskarpatent I Syd Ab Novel 3-triazolyl-galactoside inhibitors or galectins
WO2006009209A1 (en) * 2004-07-22 2006-01-26 Kaken Pharmaceutical Co., Ltd. Preventive or therapeutic agent for chronic inflammatory lung disease
WO2010126435A1 (en) 2009-04-28 2010-11-04 Forskarpatent I Syd Ab Novel galactoside inhibitors of galectins
DE102009026636B4 (en) 2009-06-02 2011-04-14 Pari Pharma Gmbh A method of welding a membrane to a carrier in the manufacture of a membrane nebulizer
US9642888B2 (en) * 2011-04-12 2017-05-09 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition

Also Published As

Publication number Publication date
EP2914269B1 (en) 2020-07-29
ES2817888T3 (en) 2021-04-08
EP3278805A1 (en) 2018-02-07
JP2015535233A (en) 2015-12-10
CA2884802A1 (en) 2014-05-08
EP2914269A1 (en) 2015-09-09
WO2014067986A1 (en) 2014-05-08
CN104755088A (en) 2015-07-01
WO2014067986A8 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
IN2015DN02573A (en)
NZ708501A (en) Treatment of pulmonary disease
IN2015DN01156A (en)
MY176814A (en) Compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
EA201491672A1 (en) HETEROCYCLINE COMPOUNDS AS MEK INHIBITORS
MX2015015412A (en) Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis.
EP2823043A4 (en) High concentration alpha-glucosidase compositions for the treatment of pompe disease
EP2827869A4 (en) Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
NZ704662A (en) Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
PH12015501494A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyrimidines
EA201491149A1 (en) PYRAZOLOPIRIDINE DERIVATIVES, METHODS OF THEIR PRODUCTION AND THEIR THERAPEUTIC USE
TN2014000095A1 (en) Pharmaceutical compositions
MX2015007916A (en) Peri-carbinols.
MX2013008340A (en) Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer.
PH12014500990A1 (en) Methods for treating gout flares
MX2015008187A (en) Deuterated alk inhibitors.
PH12015500061A1 (en) Method for preparing substituted triazolopyridines
PH12014502065A1 (en) Vesicular formulations
WO2013117503A3 (en) Pi3k inhibitors for treating fibrotic diseases
MX347541B (en) Sialic acid analogs.
PH12015502703A1 (en) Pharmaceutical compositions
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
MX2015007460A (en) Diazepine derivatives useful as calcium channel blockers in the treatment of pain.
NZ629475A (en) Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines
TN2014000227A1 (en) Method for producing substituted 5-fluoro-1h-pyrazolopyridines